Prevention, Treatment for Migraine Rapidly Evolves, Calling for Development of Novel Drugs
November 21st 2023Zavegepant (Zavzpret; Pfizer) is the first and only only CGRP receptor antagonist as a nasal spray for the acute treatment of migraine in adults with and without aura approved by the FDA.
Read More
Extended-Release Buprenorphine Found Well-Tolerated for Fentanyl Opioid Use Disorder
November 21st 2023Eligible individuals with opioid use disorder using fentanyl received a single 4 mg dose of transmucosal buprenorphine followed by the extended-release buprenorphine 300 mg injection after approximately 1 hour.
Read More
Pharmacists Play Key Role in Educating Patients About HIV Risk, Treatments
November 20th 2023In the second part of his interview with Pharmacy Times, PharmD, CSP, AAHIVP, a clinical pharmacist and subject matter expert with Shields Health Solutions, discussed pharmacists’ role in HIV education and management.
Watch
FDA Approves Enzalutamide for Nonmetastatic Castration-Sensitive Prostate Cancer
November 17th 2023The approval makes enzalutamide the first and only androgen receptor-signaling inhibitor approved for the treatment of nonmetastatic castration-sensitive prostate cancer with biochemical recurrence at high risk for metastatic.
Read More
FDA Approves Capivasertib With Fulvestrant for PIK3CA/AKT1/PTEN Alterations Breast Cancer
November 17th 2023Capivasertib is indicated for hormone receptor-positive, human epidermal growth factor 2-negative locally advanced or metastatic breast cancer with 1 or more PIK3CA/ALT1/PTEN-alterations.
Read More
Expert Discusses Investigational AVB-101 for Frontotemporal Dementia
November 17th 2023Lisa Deschamps, CEO of AviadoBio, discusses frontotemporal dementia and AVB-101, a one-time therapy designed to stop disease progression by delivering a functional copy of the GRN gene and restoring progranulin levels in the brain.
Watch